Compound ID | 2818
Class: Folate synthesis inhibitor
| Spectrum of activity: | Gram-positive |
| Details of activity: | Active against methicillin-resistant and -susceptible Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus sp., and Mycobacterium tuberculosis; membrane-active agent |
| Description: | Synthetic compound from the National Cancer Institute (NCI) diversity set V library (1,593 compounds); shows synergistic effect with cefoxitin |
| Institute where first reported: | Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, Missouri, USA |
| Year first mentioned: | 2023 |
| Development status: | Experimental |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/54676871 |
| Citation: | https://journals.asm.org/doi/10.1128/spectrum.00541-23#T3 |